The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin
Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...
Molecular Probe Techniques, Rifamycins/therapeutic use, Isoniazid/therapeutic use, Tuberculosis, Multidrug-Resistant/diagnosis, Antitubercular Agents/therapeutic use, Isoniazid/pharmacology, Rifampin/pharmacology, Mycobacterium tuberculosis/drug effects, Drug Resistance, Bacterial, Reproducibility of Results